February #44 : The “No Nukes” Movement - by Lark Lands, PhD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

They Shoot Barebackers, Don't They?

A Ride on the Wild Side

Secrets & Lies

Brain Drain

All in the Family

Is Stoning Next?

Tee'd Off

Say What

Heart to HAART


To the Editor

POZarazzi: Stardust Memories

Tee'd Off

Say What

The Stiles Files

You've Got Mail!

Ad of the Month: Oh, Good Lords!

Cry Cannabis

An Affair to Remember

Techno Truth

POZ Planet: Vital Stats

Behind the Eight Ball

Voter Fraud

Show & Tell

POZ Picks

Northern Disclosure

The Wizard of Roz


Heart to HAART

Ever Laughter

A River Ran Through Him

One Toke Over the Line

Talk Therapy

New Drug Watch

The Party’s Still On

The “No Nukes” Movement

Vits Help the Rits Go Down

Female Trouble

Not My Type

Where to Find It

Big Daddy

Aunt Evelyn's Letters

Verse: Eulogy for Brad

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

February 1999

The “No Nukes” Movement

by Lark Lands, PhD

First the bad news. Some nuked-out PWAs pinning their hopes on abacavir (Ziagen), Glaxo Wellcome’s new contender in the class of nucleoside analog reverse transcriptase inhibitors (NRTIs), may be in for trouble. Several research groups have identified two different resistance phenonema that create cross-resistance among all the nukes, including just-out abacavir. Most forms of NRTI resistance result in a one-for-one switcheroo—the exchange of one of the reverse transcriptase (RT) enzyme’s amino-acid building blocks for another. Because such mutations usually allow the virus to resist only a specific drug, others in the nuke class may still work. But with these newly found hitches—identifiable on some genotypic (viral resistance) tests—that’s not the case.
In one—the so-called 69SSS amino acid insertion—the addition of two extra amino acid building blocks to the RT enzyme causes multi-nuke resistance. In the other—the Q151M complex—a specific combination of five mutations (test-takers, observe: A62V, V751, F77L, F116Y and Q151M) has the same unfortunate result. Virco researcher Brendan Larder, MD, reports significant abacavir resistance with either of these.

Now for the good news: In studies to date, these problems with nuke cross-resistance have only been seen in 1 percent or 2 percent of participants. And not to worry: the 69SSS insertion and Q151M complex do not create resistance to the nonnucleoside RTIs or to the protease inhibitors.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has someone ever disclosed your HIV status without your permission?

Choosing Your Meds

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.